181 results on '"Chaturvedi, Anuhar"'
Search Results
2. A unique role of p53 haploinsufficiency or loss in the development of acute myeloid leukemia with FLT3-ITD mutation
3. IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction—a retrospective propensity score analysis
4. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations
5. Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators.
6. Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody
7. In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site
8. Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo
9. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML
10. Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
11. Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation
12. All-in-One inducible lentiviral vector systems based on drug controlled FLP recombinase
13. Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications
14. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML
15. A unique role of p53 haploinsufficiency or loss in the development of acute myeloid leukemia with FLT3-ITD mutation
16. A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2
17. Cell of Origin in AML: Susceptibility to MN1-Induced Transformation Is Regulated by the MEIS1/AbdB-like HOX Protein Complex
18. Rationalization of the activity Profile of Pyruvate Kinase Isozyme M2 (PKM2) Inhibitors using 3D QSAR
19. Lactonization of the Oncometabolite D-2-Hydroxyglutarate Produces a Novel Endogenous Metabolite
20. Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia
21. Lactonization of the Oncometabolite D-2-Hydroxyglutarate Produces a Novel Endogenous Metabolite
22. IDH Mutations Are Associated with an Increased Risk of Coronary Artery Disease and Cardiotoxicity in Patients with Established AML
23. IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction—a retrospective propensity score analysis
24. Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML)
25. A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.
26. Post Transplantation Measurable Residual Disease (MRD) Monitoring Using Next-Generation Sequencing Is Highly Predictive for Relapseafter Allogeneic Stem Cell Transplantation
27. Efficacy of Chemotherapy, Phd-Inhibitor Molidustat or BRD4 Inhibitor JQ1 in Combination with Targeted Inhibition of Mutated IDH1 in Human AML In Vivo
28. In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site
29. Abstract 2182: Preclincial in vitro and in vivo combination therapies for mutant IDH1R132 tumors with BAY 1436032
30. Signaling Pathways of Mutant IDH1 Independent of R-2-Hydroxyglutarate
31. Prolyl Hydroxylase 3 (Phd3) Is a Therapeutic Target in Isocitrate Dehydrogenase 1 (IDH1) Mutated Acute Myeloid Leukemia
32. IDH1/2mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction—a retrospective propensity score analysis
33. Activation of TRKA receptor elicits mastocytosis in mice and is involved in the development of resistance to KIT-targeted therapy
34. Pan-Mutant-IDH1 Inhibitor Bay-1436032 Is Highly Effective Against Human IDH1 Mutant Acute Myeloid Leukemia In Vivo
35. Pyrimethamine as a Potent and Selective Inhibitor of Acute Myeloid Leukemia Identified by High-throughput Drug Screening
36. Impact of Molecular Genetics on Disease-Free Survival in Myelofibrosis Patients Following Allogeneic Stem Cell Transplantation
37. Characteristics and Prognosis of AML Patients with or without a History of Clonal Hematopoiesis
38. Effective Treatment of Human CML By RNAi In Vivo in a Xenotransplantation Mouse Model
39. Enigmas of IDH mutations in hematology/oncology
40. Synergistic Activity of IDH1 Inhibitor Bay-1436032 with Azacitidine in IDH1 Mutant Acute Myeloid Leukemia
41. The Metabolite R-2-Hydroxyglutarate (R2HG) Collaborates with HoxA9 to Induce Monocytic Leukemia
42. Prognostic Impact of Splicing Factor Mutations in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
43. A Novel Inhibitor of Mutant IDH1 Induces Differentiation in Vivo and Prolongs Survival in a Mouse Model of Leukemia
44. High-Throughput Drug Screening Identifies Pyrimethamine As a Potent and Selective Inhibitor of Acute Myeloid Leukemia
45. Genetic Deletion of SEPT7 Reveals a Cell Type-Specific Role of Septins in Microtubule Destabilization for the Completion of Cytokinesis
46. The Clinical and Prognostic Influence Of Mutations In The Cohesin Complex In Acute Myeloid Leukemia
47. Compassionate use of sorafenib in FLT3-ITD–positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation
48. Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia
49. Mutated IDH1 Has 2-Hydroxyglutarate-Independent Functions in Leukemogenesis
50. Prognostic Significance of ASXL1 Mutations in Patients With Myelodysplastic Syndromes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.